Pancreatic Cancer Research

ResearcherUniversity Hospital OlomoucActive in the last 2 years

Bohuslav Melichar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5474-6866; OpenAlex author ID A5009523282. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 4 papers · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 20

  1. Benzoyl chloride derivatization improves selectivity and sensitivity of lipidomic quantitation in human serum of pancreatic cancer patients using RP-UHPLC/MS/M… Co-author DOI 10.1007/s00216-025-06151-0↗
  2. RP-UHPLC/MS/MS provides enhanced lipidomic profiling of human serum in pancreatic cancer. Co-author DOI 10.1016/j.aca.2025.344952↗
  3. Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum. Co-author DOI 10.1038/s43856-026-01445-5↗
  4. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  5. Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial. Co-author DOI 10.1007/s40487-024-00309-z↗
  6. Comprehensive characterization of complex glycosphingolipids in human pancreatic cancer tissues. Co-author DOI 10.1016/j.jbc.2023.102923↗
  7. Favorable prognostic significance of membranous β-catenin expression and negative prognostic significance of cytoplasmic β-catenin expression in pancreatic can… Co-author DOI 10.4149/neo_2023_230721n380↗
  8. Lipidomic profiling of human serum enables detection of pancreatic cancer. Co-author DOI 10.1038/s41467-021-27765-9↗
  9. Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alteration… Co-author DOI 10.2147/cmar.s185352↗
  10. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. First author DOI 10.2217/pgs-2018-0073↗
  11. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  12. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdw607↗
  13. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of th… Co-author DOI 10.3748/wjg.v23.i35.6420↗
  14. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗
  15. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. First author DOI 10.1007/s00280-016-3058-y↗
  16. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  17. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv133↗
  18. Role of solute carrier transporters in pancreatic cancer: a review. Co-author DOI 10.2217/pgs.14.80↗
  19. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Co-author DOI 10.1007/s00280-013-2246-2↗
  20. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? First author DOI 10.1016/j.pan.2013.09.005↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Beatrice Mohelníková-Duchoňová · 12 shared papers, 2013–2026 · strength 1.62
  2. Martin Loveček · 7 shared papers, 2017–2026 · strength 1.14
  3. Michal Holčapek · 5 shared papers, 2022–2026 · strength 1.13
  4. Ondřej Peterka · 4 shared papers, 2022–2026 · strength 0.94
  5. Zuzana Lásko · 3 shared papers, 2023–2026 · strength 0.78
  6. Milan Vošmik · 2 shared papers, 2024–2026 · strength 0.45
  7. Josef Dvořák · 2 shared papers, 2023–2024 · strength 0.37
  8. Petr Karásek · 2 shared papers, 2022–2026 · strength 0.35
  9. Pavel Souček · 5 shared papers, 2013–2019 · strength 0.35
  10. Radmila Lemstrová · 4 shared papers, 2014–2017 · strength 0.27
  11. Jan Trna · 1 shared paper, 2026 · strength 0.24
  12. Aml Mustafa Banni · 1 shared paper, 2024 · strength 0.21
  13. Igor Sirák · 1 shared paper, 2024 · strength 0.21
  14. Tomáš Zemánek · 2 shared papers, 2019 · strength 0.20
  15. Karel Hořejší · 1 shared paper, 2023 · strength 0.19
  16. R Havlík · 3 shared papers, 2017–2019 · strength 0.19
  17. Blanka Rosová · 1 shared paper, 2023 · strength 0.17
  18. Árpád Szabó · 1 shared paper, 2023 · strength 0.17
  19. Radoslav Matěj · 1 shared paper, 2023 · strength 0.17
  20. Viktor Hlaváč · 3 shared papers, 2013–2019 · strength 0.16
  21. Pavel Škrha · 1 shared paper, 2022 · strength 0.11
  22. Jan Škrha · 1 shared paper, 2022 · strength 0.11
  23. Denise Wolrab · 1 shared paper, 2022 · strength 0.11
  24. G. Deplanque · 2 shared papers, 2015–2017 · strength 0.10
  25. Jan Hlavsa · 2 shared papers, 2013–2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.